From evaluation to implementation: how to ensure efficient investment in implementation of cost-effective technologies in the real world?

TY - CONF

T1 - From evaluation to implementation

T2 - how to ensure efficient investment in implementation of cost-effective technologies in the real world?

AU - Faria, Rita

AU - Whyte, Sophie

AU - Hoomans, Ties

AU - Palmer, Stephen John

PY - 2015

Y1 - 2015

N2 - Healthcare systems have had mixed success in getting cost-effective technologies implemented in clinical practice. As a result, patients may not be offered the most appropriate treatment for their condition and miss out on potential health gains. These health gains could be realised by investing in implementation strategies such as audit-and-feedback that address the barriers to implementation. However, these investments potentially compete for the same healthcare budget and therefore need to be evaluated in a manner consistent with those used to determine the cost-effectiveness of technologies. We develop and apply value of implementation analysis to inform real-world decisions on how much to invest to increase implementation and how best to target that investment to maximise value. The discussion leaders will present a formal analytic framework to estimate the value of implementation, demonstrate its practical application to a variety of policy relevant case studies including drugs, diagnostic tests and clinical guidelines, and discuss the implications for decisions in how to prioritise investments in implementation. Rita Faria will introduce the framework, the nature of the assessments and data required, and illustrate its application to novel oral anticoagulants for the UK National Health Service (NHS). Sophie Whyte will show the application of the framework to a diagnostic device using the case study of natriuretic peptide testing in patients with suspected heart failure. Ties Hoomans will discuss the practical issues with the use of the framework to clinical guidelines. Audience participation will be encouraged with interactive discussions on the issues raised by each presentation. The workshop will finish with a chaired discussion in which the audience and speakers are invited to comment on the implications for industry, academia and decision-makers. This workshop will be of interest to analysts conducting economic evaluations based both in academia and industry and to the decision-makers using their results.

AB - Healthcare systems have had mixed success in getting cost-effective technologies implemented in clinical practice. As a result, patients may not be offered the most appropriate treatment for their condition and miss out on potential health gains. These health gains could be realised by investing in implementation strategies such as audit-and-feedback that address the barriers to implementation. However, these investments potentially compete for the same healthcare budget and therefore need to be evaluated in a manner consistent with those used to determine the cost-effectiveness of technologies. We develop and apply value of implementation analysis to inform real-world decisions on how much to invest to increase implementation and how best to target that investment to maximise value. The discussion leaders will present a formal analytic framework to estimate the value of implementation, demonstrate its practical application to a variety of policy relevant case studies including drugs, diagnostic tests and clinical guidelines, and discuss the implications for decisions in how to prioritise investments in implementation. Rita Faria will introduce the framework, the nature of the assessments and data required, and illustrate its application to novel oral anticoagulants for the UK National Health Service (NHS). Sophie Whyte will show the application of the framework to a diagnostic device using the case study of natriuretic peptide testing in patients with suspected heart failure. Ties Hoomans will discuss the practical issues with the use of the framework to clinical guidelines. Audience participation will be encouraged with interactive discussions on the issues raised by each presentation. The workshop will finish with a chaired discussion in which the audience and speakers are invited to comment on the implications for industry, academia and decision-makers. This workshop will be of interest to analysts conducting economic evaluations based both in academia and industry and to the decision-makers using their results.

M3 - Other

ER -